Fuscalpel is at the cutting edge of High-Intensity Focused Ultrasound (HIFU) technology, pioneering non-invasive medical treatments with our proprietary HIFU device. This revolutionary tool has been instrumental in supporting over 100 hospitals and has provided benefits to more than 40,000 patients around the world. Our technology distinguishes itself through innovation, having addressed and overcome numerous engineering and medical challenges.
Our device has garnered essential regulatory approvals, achieving significant milestones in the global healthcare landscape. It has navigated through the rigorous CFDA (China) approval process, earned the CE marking for Europe, and obtained licenses in crucial markets, including Korea, Taiwan, Hong Kong, and Indonesia. These accomplishments highlight Fuscalpel's significant impact as a leading force in non-invasive treatment solutions, showcasing our dedication to delivering safe and effective healthcare options worldwide.
Company Details
- Employees
- 1
- Founded
- -
- Address
- Irvine, Ca 92870, Us
- Industry
- Medical Equipment Manufacturing
- NAICS
-
Medical Equipment and Supplies ManufacturingSurgical and Medical Instrument ManufacturingSurgical Appliance and Supplies ManufacturingDental Equipment and Supplies ManufacturingOphthalmic Goods ManufacturingDental Laboratories
- Website
- https://fuscalpel.com
- HQ
- Irvine, CA
Fuscalpel Medical Questions
Fuscalpel Medical's website is https://fuscalpel.com
Fuscalpel Medical's LinkedIn profile is https://www.linkedin.com/company/fuscalpel
Fuscalpel Medical has
1 employees.
View email and phone details for 1
employees at Fuscalpel Medical.
Fuscalpel Medical's industry is
Medical Equipment Manufacturing
Fuscalpel Medical's top competitors are
Digital Arches,
Neptune Medical,
Makani Science,
Lumitron Technologies Inc.,
Koya Medical, Inc.,
Qnovia, Inc.,
Novoheart,
Metronom Health,
Pretika Medtech Corporation,
Sayenza Biosciences.
Fuscalpel Medical's categories are Medical Equipment Manufacturing
Fuscalpel Medical's founding year is 2024
